ClinicalTrials.gg
CompletedNCT03571087Updated Aug 14, 2018

Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia

A Phase 3 interventional study of HL140 5/10 and HL140 10/10 in Primary Hypercholesterolemia, sponsored by Hanlim Pharm. Co., Ltd.. Completed. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-08-14.

Sponsored by Hanlim Pharm. Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
374
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Enrollment
25th of 57
374 · median 203
Started
2014
with 2 others
Phase 3
33 of 59
none open now
Registered
51st of 59
by date
Lead sponsor
2 of 59
Hanlim Pharm. Co., Ltd.

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 25th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2014, is one of 33 in phase 3, and was the 51st registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of HL140 in patients with primary hypercholesterolemia.

Read the detailed description

The purpose of this study is to demonstrate that the efficacy of combination drug of rosuvastatin/ezetimibe is superior to single rosuvastatin drug and to confirm the safety of combination drug of rosuvastatin/ezetimibe

03

Conditions studied

  • Primary Hypercholesterolemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged over 19 years
  • Signed form
  • At visit 1 and visit 2, LDL-Cholesterol ≤ 250mg/dL and Triglyceride ≤ 400mg/dL

Exclusion criteria

Exclusion Criteria:

  • At visit 1, ≥ 30kg/㎡
  • Has a history of myopathy or rhabdomyolysis cased by statin treatment, hereditary myopathy or family history and to statin(HMG-CoA reductase inhibitor) and component of ezetimibe
  • Has a Severe renal disorder(Ccr \<30mL/min) or nephrotic syndrome
  • Creatine Kinase > 5 x
  • or AST > 3 x upper limit of normal
  • Has a activity/chronic hepatic disease or -positive
  • Has a endocrine or metabolic diseases known to affect the serum phospholipid or protein

    • Uncontrolled diabetes mellitus( ≥9%)
    • Hypothyroidism (TSH > 1.5 x upper limit of normal rate at the screening )
  • Uncontrolled hypertension (SBP ≥180mmHg or DBP ≥110mmHg)
  • Has a acute arteriopathy(history of unstable angina, cardiac infarction, transient ischemic stroke, cerebrovascular disease, coronary artery bypass, coronary intervention within 12 weeks prior to screening)
  • Severe heart failure ( Class III or IV)
  • Has a drug absorption disorder by gastrointestinal surgery or gastrointestinal disorder
  • History of malignant tumor including myelogenous and lymphoma within 5 years (Participation is possible, if the tumor has not recurred for more than 5 years)
  • Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption
  • Female subjects of who disagree with the methods(surgical sterilization, intrauterine device or condoms)
  • Pregnant or breast-feeding
  • Patients who have a drug or alcohol abuse or are being treated for psychological disorder
  • Patients who were treated with other drug within 12 weeks prior to screening
  • Other patients who are inappropriate to participate in the study considered by the investigator or other study staffs
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
374 participants (actual)

Study arms

  • Experimental
    HL140 5/10

    Treatment(W0\~W8), Extension(W9\~W20): : 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)

    Drug: HL140 5/10

  • Experimental
    HL140 10/10

    Treatment(W0\~W8), Extension(W9\~W20): : 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)

    Drug: HL140 10/10

  • Experimental
    HL140 20/10

    Treatment(W0\~W8), Extension(W9\~W20): : 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)

    Drug: HL140 20/10

  • Experimental
    Rosuvastatin 5mg → HL140 5/10

    1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg 2. Extension period(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)

    Drug: Rosuvastatin 5mg → HL140 5/10

  • Experimental
    Rosuvastatin 10mg → HL140 10/10

    1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg 2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)

    Drug: Rosuvastatin 10mg → HL140 10/10

  • Experimental
    Rosuvastatin 20mg → HL140 20/10

    1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 20mg 2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)

    Drug: Rosuvastatin 20mg → HL140 20/10

Interventions

  • DrugHL140 5/10

    1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇ ●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo

  • DrugHL140 10/10

    1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇ ○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo

  • DrugHL140 20/10

    1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo

  • DrugRosuvastatin 5mg → HL140 5/10

    Drug page: Rosuvastatin

    1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo 2. Extension period(W9\~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇ * HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo

  • DrugRosuvastatin 10mg → HL140 10/10

    Drug page: Rosuvastatin

    1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo 2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇ * HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo

  • DrugRosuvastatin 20mg → HL140 20/10

    Drug page: Rosuvastatin

    1. Treatment(W0\~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg 2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo

06

What researchers measure

Primary outcomes

  1. Percentage change in LDL-Cholesterol from baseline

    Percentage change(%) in LDL-Cholesterol from baseline at week 8

    Time frame: Week 8

Secondary outcomes

  1. Percentage change in LDL-Cholesterol from baseline

    Percentage change(%) in LDL-Cholesterol from baseline at week 4

    Time frame: Week 4

  2. Percentage change in TG from baseline

    Percentage change(%) in TG from baseline at week 4 and week 8

    Time frame: Week 4, Week 8

  3. Percentage change in TC from baseline

    Percentage change(%) in TC from baseline at week 4 and week 8

    Time frame: Week 4, Week 8

  4. Percentage of change in non-HDL-Cholesterol

    Percentage change(%) in non-HDL-Cholesterol from baseline at week 4 and week 8

    Time frame: Week 4, Week 8

  5. Percentage of change in HDL-Cholesterol

    Percentage change(%) in HDL-Cholesterol from baseline at week 4 and week 8

    Time frame: Week 4, Week 8

  6. Percentage of change weeks in Apo A-I

    Percentage change(%) in Apo A-I from baseline at week 4 and week 8

    Time frame: Week 4, Week 8

  7. Percentage of change in Apo B

    Percentage change(%) in Apo B from baseline at week 4 and week 8

    Time frame: Week 4, Week 8

  8. Percentage of change in Lipoprotein(a)

    Percentage change(%) in Lipoprotein(a) from baseline at week 4 and week 8

    Time frame: Week 4, Week 8

  9. The rate of change in hs-CRP

    Percentage change(%) in hs-CRP from baseline at week 4 and week 8

    Time frame: Week 4, Week 8

  10. Percentage of patients reached treatment goals according to NCEP ATP III Guideline

    Percentage(%) of patients reached treatment goal, by NCEP ATP III guideline, at week 4 and week 8

    Time frame: Week 4, Week 8

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2018
First posted
Jun 27, 2018
Start
Sep 2014
Primary completionActual
Aug 2015
CompletionActual
Sep 2015
Last update
Aug 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03571087
Responsible party
Sponsor
First posted
Jun 27, 2018
Start date
Sep 2014
Primary completion
Aug 2015
Completion
Sep 2015
Last update
Aug 14, 2018

Study contacts

Kisik Kim
study chair · The Catholic University of Korea, Dagu St. Mary's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion